盐酸齐拉西酮与利醅酮治疗精神分裂症的疗效及安全性比较  

Comparison of efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia

作　　者：卢殿军[1] 宁洁[1] 吴胜[1] 

机构地区：[1]重庆市精神卫生中心,401147

出　　处：《重庆医学》2011年第17期1693-1694,共2页Chongqing medicine

摘　　要：目的评价盐酸齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性。方法选择住院精神分裂症患者60例,随机分为齐拉西酮组(n=30,口服盐酸齐拉西酮片)与利培酮组(n=30,口服利培酮片),疗程6周。采用精神分裂症阳性与阴性症状评定量表(PANSS)评价其临床疗效,不良反应量表(TESS)评价其安全性。结果治疗结束时,齐拉西酮组PANSS减分率为(60.98±24.04)%,利培酮组PANSS减分率为(62.03±28.29)%,组间比较差异无统计学意义(P>0.05);齐拉西酮组不良反应发生率与利培酮组比较差异无统计学意义(P>0.05)。结论盐酸齐拉西酮的疗效及不良反应与利培酮相当,是有效、安全的抗精神病药物。Objective To evaluate clinical efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia.Methods 60 patients with schizophrenia in hospital were selected and randomly divided into ziprasidone group（n=30,ziprasidone administrated orally） and risperidone group（n=30,risperidone tablet administrated orally）,with a 6-week course of treatment.Positive and negative syndrome scale（PANSS） was used to assess their clinical efficacy and the treatment emergent symptom scale（TESS） was adopted to investigate their safety.Results At the end of treatment,PANSS reduced score rate of ziprasidone group was（60.98±24.04）%,and that of risperidone group was（62.03±28.29）%,with no statistically significant difference between the two groups（P0.05）.Compared incidence rate of side effects of patients in ziprasidone group with that in risperidone group,no statistically significant difference was found between the two groups（P0.05）.Conclusion Ziprasidone hydrochloride is an effective and safe antipsychotic agent with similar curative efficacy and adverse reaction to risperidone.

关 键 词：抗精神病药 精神分裂症 盐酸齐拉西酮 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]